Company news
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) news
Acumen Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 10, 2026: Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Press releases & updates
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
September 10, 2026
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
August 12, 2026
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
August 5, 2026
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 15, 2026
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 7, 2026
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
June 16, 2026
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
May 12, 2026
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
May 7, 2026
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
May 5, 2026
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
March 26, 2026
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
March 19, 2026
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 17, 2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
March 15, 2026
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 10, 2026
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 3, 2026
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 2, 2025
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 18, 2025
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
November 17, 2025
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
November 12, 2025
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
November 10, 2025
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
November 5, 2025
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 4, 2025
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2025
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
August 12, 2025
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
August 5, 2025
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
July 28, 2025
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
July 15, 2025
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
July 15, 2025
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
July 10, 2025
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
May 13, 2025
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
May 7, 2025
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
May 6, 2025
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
April 2, 2025
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
March 27, 2025
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
March 26, 2025
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
March 20, 2025
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
March 19, 2025
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s
March 18, 2025
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
March 12, 2025
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
January 8, 2025
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
November 11, 2024
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
November 5, 2024
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
September 25, 2024
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
September 24, 2024
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
August 12, 2024
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 28, 2024
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 13, 2024
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 7, 2024
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 6, 2024
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 3, 2024